• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Geron Shares Rise on Fast Track Designation -- Biotech Movers

The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.
By ARMIE MARGARET LEE Oct 31, 2017 | 09:26 AM EDT
Stocks quotes in this article: ACOR, JNJ, INCY, GERN, AZN

Shares of Geron Corp. (GERN) rose 9.7% to $2.26 in premarket trading after the U.S. Food and Drug Administration gave fast track designation to a key drug to the company's portfolio.

The Menlo Park, Calif.-based company said its, imetelstat drug was given fast track designation as a potential treatment for adults with transfusion-dependent anemia due to Low or Intermediate-1 risk myelodysplastic syndromes (MDS) who are non-del(5q) and who are refractory or resistant to treatment with an erythropoiesis stimulating agent.

Imetelstat was initially developed by Geron and exclusively licensed to Johnson & Johnson's (JNJ) Janssen Biotech Inc. on a worldwide basis.

Tuesday's announcement came a day before Geron is slated to release its third-quarter results.

Meanwhile, shares of Acorda Therapeutics  Inc. (ACOR) were down 5.7% to $25.75. The Ardsley, N.Y.-based company reported third-quarter non-GAAP net income of  $20.1 million, or $0.43 per diluted share, compared with a net loss of $1.9 million, or $0.04 per diluted share in the year-ago period. Revenue was $141.07 million, compared with $135.61 million.

Acorda president and CEO Ron Cohen said in a statement that the firm plans to resubmit its new drug application for Inbrija in the fourth quarter. The company in August received a refusal to file letter from the FDA regarding its application for Inbrija, a potential treatment for people with Parkinson's disease.

Also on Tuesday, Cohen said the company is on pace to announce top-line results from its Phase 3 study of tozadenant, another potential therapy for Parkinson's disease, in the first quarter of 2018.

Among the other biotech stock movers was Incyte Corp. (INCY) , up 3.3% to $118. The Wilmington, Del.-based firm reported net income of $36 million, or $0.17 per basic and diluted share, compared with net income of $37 million, or $0.20 per basic and $0.19 per diluted share in the same period last year. Revenue was $381.5 million, compared with $269.5 million.

Incyte also got welcomed news as AstraZeneca plc (AZN) said it signing a deal with Incyte under which the two companies will start a final-stage Phase III clinical trial next year for immunotherapy combination treatments to fight lung cancer.

"Expansion of the clinical collaboration with AZN (MP) announced this morning significantly broadens the revenue opportunity set for IDO inhibitor epacadostat, with a Phase III trial planned in combination with Imfinzi in patients with Stage III unresectable non-small cell lung cancer (NSCLC), building on AZN's recent PACIFIC trial success," wrote Michael Schmidt of Leerink Partners in a note Tuesday morning. "Other pipeline items remain on track."

Leerink has an outperform rating on Incyte.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Broad Rally, Vaccine Optimism, Johnson & Johnson, GameStop Roars, Trading Nvidia

Stephen Guilfoyle
Feb 25, 2021 7:04 AM EST

The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Bruce Kamich
Feb 23, 2021 7:43 AM EST

Let's review the charts and indicators.

It's an Opportune Time to Renew Your Vows With CVS Health

Paul Price
Feb 18, 2021 7:00 AM EST

The pharmacy giant offered a great buy/write options play last summer and is setting up again for such action.

Just Had My First Teladoc Appointment: Is the Rally Over?

Bruce Kamich
Feb 17, 2021 2:39 PM EST

I may be late to trends, but not to stock charts.

CVS Health Reports Q4, and Here's What I'm Changing Up

Stephen Guilfoyle
Feb 16, 2021 10:55 AM EST

I do want to give new CEO Karen Lynch a chance. Nothing against Larry Merlo but I always thought that this stock was undervalued.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login